Regeneron Acquires 23andMe in Court-Supervised Sale
23andMe, a consumer genetics and biotechnology company, has entered into a definitive agreement to be acquired by Regeneron Pharmaceuticals...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Innovation Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
23andMe, a consumer genetics and biotechnology company, has entered into a definitive agreement to be acquired by Regeneron Pharmaceuticals...
EXACT Therapeutics announced positive final data from its Phase 1 ACTIVATE trial, demonstrating that Acoustic Cluster Therapy (ACT) significantly...
CRISPR Therapeutics and Sirius Therapeutics have partnered to develop and commercialize SRSD107, a long-acting siRNA therapy for thromboembolic disorders....
BridgeBio Pharma released data from its Phase 3 ATTRibute-CM trial of acoramidis, showing a link between early, sustained increases...
Kymera Therapeutics announced preclinical data for KT-621, an oral STAT6 degrader, showing its potential as a once-daily treatment for...
The Coalition to Transform Clinical Trial Engagement (CTCTE) launched the Champions for Change – Paid Time Off (PTO) Initiative...
NovelMed’s Ruxoprubart, a novel complement-targeting immunotherapy, has shown positive interim results in a Phase II trial for Paroxysmal Nocturnal...
Prime Medicine announced positive initial clinical trial data for PM359, a prime-edited cell therapy for Chronic Granulomatous Disease (CGD)....
SELLAS Life Sciences Group announced the first pediatric patient with acute myeloid leukemia (AML) has been dosed in a...
Excision BioTherapeutics announced preclinical data demonstrating the efficacy of EBT-107, a CRISPR-based gene therapy candidate for chronic hepatitis B...